Rapid infliximab infusions are generally well-tolerated in children with inflammatory bowel disease
نویسندگان
چکیده
منابع مشابه
Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
AIM To study the safety and effectiveness associated with accelerated infliximab infusion protocols in patients with inflammatory bowel disease (IBD). METHODS Original protocols and infusion rates were developed for the administration of infliximab over 90-min and 60-min. Then the IBD patients on stable maintenance infliximab therapy were offered accelerated infusions. To be eligible for the ...
متن کاملPeripheral neuropathy with infliximab therapy in inflammatory bowel disease.
To the Editor: Antitumor necrosis factor alpha (antiTNF ) agents have provided an important breakthrough in the management of patients with inflammatory bowel disease (IBD), leading to high remission rates, fistula closure, and improved quality of life. However, they are not without serious adverse effects, including lymphoma, infection, bowel obstruction, and neuropathy.1 This case report illu...
متن کاملAuto-antibodies in Patients with Inflammatory Bowel Disease Unclassified
Background: Inflammatory bowel disease unclassified (IBDU) is considered to be an aberrant immune response with loss of tolerance to many antigens. Objective: This paper tries to address whether there is any value to test for auto-antibodies in such patients. Methods: 60 patients with inflammatory bowel disease unclassified participated in the study. Auto-antibodies to nuclear antigen, intestin...
متن کاملSerum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
The role of trough serum infliximab (s-IFX) and antibodies toward IFX (ATI) during maintenance treatment remains unclear in children. The aim of the present study was to investigate trough s-IFX and ATI to identify any correlation with inflammatory activity and clinical response in a pediatric inflammatory bowel disease (IBD) cohort. We investigated the s-IFX trough levels in pediatric IBD pati...
متن کاملManagement of inflammatory bowel disease in poor responders to infliximab
Infliximab (IFX) is an effective treatment for inducing and maintaining response in Crohn's disease and ulcerative colitis patients. Some patients present lack of response or loss of response to IFX during maintenance therapy. Empirical management with combination therapy with an immunomodulator, IFX dose escalation, or switching IFX for another antitumor necrosis factor-α drug, mainly adalimum...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Paediatrics and Child Health
سال: 2017
ISSN: 1034-4810
DOI: 10.1111/jpc.13384